Current Opinion and Practice on Peritoneal Carcinomatosis Management: The North African Perspective

Amine Souadka 1*, Hajar Essangri 1, Amin Makni 2, Mourad Abid 3, Mouna Ayadi 4, Feriel Ksantini 4, Zakia Kordjani 3, Yousri Ballah 3, Jemila Bouka 3, Amine Benkabbou 1, Mohammed Anass Majbar 1, Basma El Khannoussi 6, Raouf Mohsine 1, Saber Boutayeb 7 and Martin Hubner 8

1 Surgical Oncology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco, 2 Surgical Oncology Department, Batna Cancer Institute, Batna, Algeria, 3 Medical Oncology Department, Salah-Azaiz Institute, Tunis, Tunisia, 4 Surgical Oncology Department, National Institute of Oncology, Houssinet, Mauritania, 5 Pathology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco, 7 Medical Oncology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco, 6 Department of Visceral Surgery, University Hospital Centre Hopitalier Universitaire Vaudois and University of Lausanne (UNIL), Lausanne, Switzerland

Background: The status of peritoneal surface malignancy (PSM) management in North Africa is undetermined. The aim of this study was to assess and compare current practice and knowledge regarding PSM and examine satisfaction with available treatment options and need for alternative therapies in North Africa.

Methods: This is a qualitative study involving specialists participating in PSM management in North Africa. The survey analyzed demographic characteristics and current knowledge and opinions regarding PSM management in different institutions. We also looked at goals and priorities, satisfaction with treatment modalities and heated intraperitoneal chemotherapy (HIPEC) usefulness according to specialty, country, years of experience, and activity sector.

Results: One-hundred and three participants responded to the survey (response rate of 57%), including oncologists and surgeons. 59.2% of respondents had more than 10 years experience and 45.6% treated 20–50 PSM cases annually. Participants satisfaction with PSM treatment modalities was mild for gastric cancer (3/10 [IQR 2–3]) and moderate for colorectal (5/10 [IQR 3–5]), ovarian (5/10 [IQR 3–5]), and pseudomyxoma peritonei (5/10 [IQR 3–5]) type of malignancies. Good quality of life and symptom relief were rated as main priorities for treatment and the need for new treatment modalities was rated 9/10 [IQR 8–9]. The perceived usefulness of systemic chemotherapy in first intention was described as high by 42.7 and 39.8% of respondents for PSM of colorectal and gastric origins, while HIPEC was described as highly useful for ovarian (49.5%) and PMP (73.8%) malignancies.

Conclusions: The management of PSM in the North African region has distinct differences in knowledge, treatments availability and priorities. Disparities are also noted...
according to specialty, country, years of expertise, and activity sector. The creation of referral structures and PSM networks could be a step forward to standardized PSM management in the region.

**Keywords: peritoneal carcinomatosis, LMIC, surveys and questionnaires, North Africa, HIPEC, PIPAC**

## INTRODUCTION

Peritoneal surface malignancy (PSM) is a rare and challenging pathology resulting from the neoplastic progression of different types of primary malignancies. Due to late diagnosis, rapid progression and limited treatment options, PSM was considered until recently as a terminal illness. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a therapy associated with significant benefits for selected patients with PSM of colorectal (1–3), gastric (4–6), and ovarian origin (7), as well as pseudomyxoma peritonei (8), therefore, changing the historical perception on peritoneal metastases. Other therapies such as perioperative systemic chemotherapy, pressurized intraperitoneal aerosol chemotherapy (PIPAC), and pulsed low dose radiation therapy are also showing promise (9–11), which is resulting in a growing acceptance. However, although a number of centers are venturing in the treatment of peritoneal malignancies and developing specialized programmes, evidence has shown that consideration of this procedure as a treatment option can be low (12). In fact, consideration of these treatment options remains low especially in non-oncologic departments (12), and discrepancies have been noted also between surgical and non-surgical oncologists (13). It appears therefore important to increase awareness and knowledge dissemination regarding these therapies within the cancer care community.

Several studies demonstrated other challenges hindering the acceptance and adoption of PSM treatment strategies, such as the lack of a multidisciplinary approach to patient management (14), the need for specialized training and mentorship but also financial restrictions to establish reference centers for referrals (15–17). These constraints are even worse in low and middle-income countries where cancer care faces additional barriers limiting the access to chemotherapy agents, radiation therapy, and surgical care (18) and where overall healthcare may differ between private and public healthcare systems (19).

North Africa is a diverse region consisting of the five countries forming the Maghreb, namely Morocco, Algeria, Tunisia, Mauritania, and Libya. This region has particular characteristics when it comes to healthcare in general with the public and private sectors playing a complementary role (20) and where cancer incidence has a distinct pattern that completely differs from that of Central and Southern African countries as well as Europe (21). Nonetheless, there is no available data on the knowledge and practices in the management of PSM in this region, except for a few reports (22). The aim of this study was to assess and compare current practice and knowledge regarding PSM and examine satisfaction with available treatment options and need for alternative therapies in North Africa.

## MATERIALS AND METHODS

### Study Design and Participants

We conducted a qualitative study among a network of specialized North Africa centers which includes all cancer centers involved in the management of PSM in the private and public sector. Representatives from each one of the five countries were contacted in order to help identify institutions undertaking PSM management and a minimum of two participants per center was required. The study was approved by the institutional review boards of all participating centers and was exempt from ethics committee approval as participants gave their consent to participate in the survey. Two similar studies have been previously conducted in a Swiss oncological network (23) and an Indian peritoneal surface malignancy network (24).

The survey included questions on demographics such as country, subspecialty, year of expertise, and number of patients treated personally with PSM. We also examined PSM management in the different institutions, and specialists current knowledge and opinions concerning carcinomatosis. We requested participants to rate on a 5 point likert scale PSM treatment goals and priorities, namely cure, symptom relief, few side effects, few contraindications, inexpensive, or providing a good quality of life. The usefulness of heated intraperitoneal chemotherapy and systemic chemotherapy (in first and second intention) was also assessed, being either poor, moderate or high for PSM of colorectal, ovarian, gastric, and pseudomyxoma peritonei origins. Participants were also required to rate their satisfaction with treatment options on a scale ranging from frustrated: 0 to perfectly happy: 10, as well as the need for new treatment options with 0: no need and 10: urgent need (23, 24). An additional section was included to analyze current practice in the management of PSM originating from pseudomyxoma peritonei tumors. In total, the survey included 29 questions (Appendix 1).

### Statistical Analysis

We reported categorical variables as numbers and percentages, and continuous variables as mean and standard deviations (SD). $\chi^2$ tests of association were used to compare respondents characteristics and when more than 25% of the subgroups examined were populated by fewer than five respondents, Fisher’s exact test or likelihood ratios were performed. Four subgroup analyses were undertaken comparing satisfaction with current treatment modalities, priorities, and perceived need of new treatment options between participants according to specialty (oncologist vs. surgeons), country, years of experience (> or <10 years of experience) and activity sector (public vs. private). Differences were tested with the non-parametric Mann–Whitney U-test and Kruskal–Wallis test as adequate. All statistical analyses
| Country      | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|--------------|-------------------|----------|-------------|------|---------|--------|------|
| Morocco      | 75 (72.8)         | 32 (72.7)| 43 (72.9)   | 0.154| 33 (94.3)| 42 (61.8)<0.001 |
| Tunisia      | 10 (8.7)          | 7 (15.9) | 3 (5.1)     | 2 (5.7)| 8 (11.8)|        |      |
| Algeria      | 13 (12.6)         | 3 (6.8)  | 10 (16.9)   | 0    | 13 (19.1)|        |      |
| Mauritania   | 5 (4.9)           | 2 (4.5)  | 3 (5.1)     | 0    | 5 (7.4) |        |      |

| Activity sector | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|-----------------|-------------------|----------|-------------|------|---------|--------|------|
| Private         | 35 (25)           | 21 (47.7)| 14 (23.7)   | 0.011|        |        |      |
| Public          | 68 (66)           | 23 (52.3)| 45 (76.3)   |      |        |        |      |

| MDT meeting  | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|--------------|-------------------|----------|-------------|------|---------|--------|------|
| Yes          | 92 (89.3)         | 40 (90.9)| 52 (88.1)   | 0.756| 28 (80) | 64 (94.1)| 0.503|
| No           | 11 (10.7)         | 4 (8.1)  | 7 (11.9)    | 7 (20)| 4 (6.9) |        |      |

| Years of experience since board qualification | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|-----------------------------------------------|-------------------|----------|-------------|------|---------|--------|------|
| <10 years                                    | 41 (39.8)         | 10 (22.7)| 31 (52.5)   | 0.045| 8 (22.9)| 33 (48.5)| 0.248|
| >10 years                                    | 61 (59.2)         | 34 (77.27)| 28 (47.5)   | 27 (77.1)| 35 (55.5)|        |      |

| Specialty | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|-----------|-------------------|----------|-------------|------|---------|--------|------|
| Oncologist| 59 (57.3)         |        |             |      | 14 (40)| 45 (66.2)| 0.011|
| Surgeon   | 44 (42.7)         |        |             |      | 21 (60)| 23 (33.8)|        |

| Surgical subspecialties | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|-------------------------|-------------------|----------|-------------|------|---------|--------|------|
| General surgeon         | 29 (72.5)         |        |             |      | 8 (80)  | 21 (70) | 0.389|
| Colorectal surgical oncologist | 9 (22.5) |        |             |      | 1 (10)  | 8 (26.7)|        |
| Gynecological surgical oncologist | 2 (5) |        |             |      | 1 (10)  | 1 (3.3) |        |

| Patients with PC personally treated annually | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|----------------------------------------------|-------------------|----------|-------------|------|---------|--------|------|
| <20                                          | 33 (26)           | 21 (64.7)| 12 (36.8)   | 0.009| 13 (39.4)| 20 (60.6)| 0.723|
| 20–50                                        | 47 (35.6)         | 4 (8.5)  | 1 (2)       |      | 15 (30)| 32 (70) |      |
| >50                                          | 23 (22.4)         | 19 (82.6)| 46 (76.9)   |      | 7 (30)  | 16 (66.7)|      |

| Guidelines followed by institution | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|------------------------------------|-------------------|----------|-------------|------|---------|--------|------|
| National                           | 12 (11.7)         | 8 (66.7)| 4 (33.3)    | 0.159| 4 (33.3)| 8 (66.7)| 0.545|
| French                             | 81 (78.6)         | 31 (38.3)| 50 (62.7)   | 26 (32.1)| 55 (67.9)|        |      |
| PSOGI                              | 10 (9.7)          | 5 (50)   | 5 (50)      |      | 5 (50)  | 5 (50)   |      |

| Personal knowledge on PCI calculation method | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|---------------------------------------------|-------------------|----------|-------------|------|---------|--------|------|
| Yes                                         | 48 (46.6)         | 25 (52)| 23 (48)    | 0.073| 18 (37.2)| 30 (62.8)| 0.481|
| No                                          | 55 (53.4)         | 19 (34.5)| 36 (66)    |      | 17 (33)| 38 (67) |      |

| Treatment options offered at institution | Global population | Surgeons | Oncologists | $P$  | Private | Public | $P$  |
|------------------------------------------|-------------------|----------|-------------|------|---------|--------|------|
| Cytoreductive surgery                    |                   |          |             |      |         |        |      |
| Yes                                      | 74 (71.8)         | 32 (72.7)| 42 (71.2)   | 0.863| 25 (71.4)| 49 (72.1)| 0.946|
| No                                       | 29 (28.2)         | 12 (41.4)| 17 (58.6)  |      | 10 (34.8)| 19 (65.2)|      |

| HIPEC                                    |                   |          |             |      |         |        |      |
| Yes                                      | 27 (26.2)         | 8 (30)   | 19 (70)    | 0.109| 9 (33.3)| 18 (66.7)| 0.934|
| No                                       | 76 (73.8)         | 36 (47.4)| 40 (52.6)  |      | 26 (66.7)| 50 (33.3)|      |

| Systemic chemotherapy                    |                   |          |             |      |         |        |      |
| Yes                                      | 91 (88.3)         | 32 (35.2)| 59 (65)    | <0.001| 29 (31.9)| 62 (68.1)| 0.330|
| No                                       | 12 (11.7)         | 12 (100)| 0 (0)      |      | 6 (54.5)| 4 (45.5)|      |

| Intraperitoneal therapy using a catheter  |                   |          |             |      |         |        |      |
| Yes                                      | 1 (1)             | 0 (0)    | 1 (100)    | 1.000| 1 (100)| 0 (0)   | 0.340|
| No                                       | 99 (99)           | 44 (44)| 58 (58)    |      | 34 (34)| 64 (64)|      |

| Pressurized intraperitoneal chemotherapy  |                   |          |             |      |         |        |      |
| Yes                                      | 3 (2.9)           | 2 (66.7)| 1 (33.3)   | 0.574| 3 (66.7)| 0 (33.3)| 0.037|
| No                                       | 100 (97.1)        | 42 (42)| 58 (58)    |      | 32 (32)| 68 (32)|      |

| Low dose radiotherapy                    |                   |          |             |      |         |        |      |
| Yes                                      | 12 (11.7)         | 5 (41.7)| 7 (58.3)   | 0.938| 8 (66.7)| 4 (33.3)| 0.020|
| No                                       | 91 (88.4)         | 39 (43)| 52 (57)    |      | 27 (29)| 64 (71)|      |

(Continued)
were performed using SPSS version 25. A significant P-value was considered if $p < 0.05$.

RESULTS

Participants and Institutions

Demographics

The representatives of the four North African countries identified 18 cancer care centers including 180 potentially eligible specialists. In total, 103 participants responded to the survey (response rate of 57%), being either oncologists or surgeons directly involved in the management of PSM in private or public healthcare facilities.

Overall, 59.2% of respondents had more than 10 years experience with 45.6% personally treating 20–50 PC cases annually. There was a significantly higher percentage of surgeons with more than 10 years than oncologists (77.27 vs. 47.5, $P = 0.045$), however, more oncologists reported treating more than 50 PC cases annually (76.9 vs. 43.1 for surgeons, $P = 0.009$). While 88.3 and 71.8% of participating institutions offered systemic chemotherapy and cytoreductive surgery, respectively, only 26.2% had access to HIPEC, with no difference between the private and public sectors ($P = 0.934$). Other treatment modalities such as low dose radiotherapy, pressurized intraperitoneal chemotherapy, were possible in 11.7, 2.9% of institutions, respectively, with a significantly higher percentage of availability in the private sector ($P = 0.020$ and 0.037). Sociodemographic details of the participants in general and according to their subgroups are presented in Table 1.

Satisfaction

Details on respondents’ satisfaction are described in Figure 1.

Participants satisfaction with PSM treatment modalities was examined according to cancer origin and was mild for gastric cancer (3/10 [IQR 2–3]) and moderate for colorectal (5/10 [IQR 3–5]), ovarian (5/10 [IQR 3–5]), and pseudomyxoma peritonei (5/10 [IQR 3–5]) type of malignancies. The need for new treatment modalities was rated 9/10, [IQR 8–9]. The comparison of the degree of satisfaction according to specialty, country, activity sector, and years of experience showed no statistically significant difference between these subgroups. On the other hand, oncologists reported a higher need for new treatment modalities (9.07 ± 0.98) compared to surgeons (8.02 ± 2.26), $P = 0.05$ (Table 2).

Goals and Priorities

79.6 and 76.7% of participants rated good quality of life and symptom relief as very important, while few contraindications and inexpensive treatments were rated less important (Figure 2).

Looking at treatment goals according to the different subgroups, oncologists rated a statistically significant higher degree of priority for all elements, except for inexpensiveness ($P = 0.287$), while prioritizing fewer contraindications was different between countries ($P = 0.049$). No significant variation was established in the priorities according to years of experience and activity sector (Table 2).

Usefulness of Systemic Chemotherapy and HIPEC in Resectable Peritoneal Metastasis

Overall, the perceived usefulness of systemic chemotherapy in first intention was described as high by 42.7 and 39.8% of respondents for PSM of colorectal and gastric origins, while HIPEC was described as highly useful for ovarian (49.5%) and PMP (73.8) malignancies.

Subgroup analysis yielded a significant difference between surgeons and oncologists, with 91.5% oncologists rating systemic chemotheraphy as a second line intention for PC of ovarian origin as highly useful, compared to 75% of surgeons ($P = 0.044$). Differences were also noted in the perceived usefulness for systemic chemotherapy in first line intention for PC of colorectal ($P = 0.030$) and gastric origin ($P = 0.029$) between specialists from the private and public sector.

Details on the usefulness of chemotherapy and HIPEC in the management of resectable peritoneal metastasis are demonstrated in Table 3.

DISCUSSION

PSM can occur as a primary malignancy, or originate from the progression of an array of tumors, such as gastric, colorectal, or ovarian cancers. In the case of metastatic spreading, this can be justified using either one of the two main hypotheses whereby tumor progression can be promoted by anatomical factors such as the local spreading of tumor cells after breaching the initial site or...
by the “seed-and-soil” hypothesis implying the specific tropism of tumor cells circulating in the lymphatic or vascular systems to certain organs. However, unknown alternative biological routes may also exist (27–29). As such, management options also vary according to tumor origins, and whether the aim of treatment is curative or palliative. This study depicts the heterogeneous knowledge on the management of PSM, differences in priorities, and lack of guideline use and standardization. Furthermore, it underlines potential differences between specialists according to specialty, country, years of expertise, and activity sector. Efforts are needed to disseminate knowledge and awareness through the creation of networks and referral structures in order to offer optimal care to the largest possible number of patients.

This survey targeted the network of cancer care centers involved in the management of PSM in North Africa, which comprises oncologists and surgeons from Morocco, Algeria, Tunisia, and Mauritania. Overall, almost half of participants reported personally treating 20–50 patients annually. However, access to HIPEC or other therapies such as PIPAC or low dose radiotherapy was poor. In case of HIPEC unavailability, 35.9% of respondents choose patient transfer to a specialized center as an alternative, while only 7.6% of respondents sought either palliative chemotherapy or cytoreductive surgery as a substitute, which could convey an overall good understanding of PSM’s changing prognosis and the acceptance of HIPEC as a potentially curative treatment option.

The results from our study were comparable to the two previous surveys conducted in the Swiss (23) and Indian networks (24). In fact, similarities were noted between the three networks, with a particular lack of satisfaction for gastric cancer compared to other origins of malignancies, which could be due to the extremely bad prognosis of PSM of this origin (30). That being said, the need for new treatment modalities was also rated as high. On the other hand, although the cost of treatment was the least important treatment goal in all three surveys, other priorities differed with a higher importance given to good quality of life by North African specialists, while cure was ranked as the main goal in the other studies. This could uncover a common misconception about quality of life decline in the treatment of PSM (31). As regards the degree of usefulness of chemotherapy and HIPEC, all three networks recognize a moderate to high usefulness of these therapies in ovarian and colorectal cancer as a first or second line treatment, with less perceived advantages for PC of gastric origin despite regional recommendations that conform to the international guidance (32). We also examined the degree of satisfaction and perceived usefulness of chemotherapy and HIPEC in the case of primary PC originating from pseudomyxoma peritonei, which illustrated...
TABLE 2 | Subgroup analysis of priorities and degree of satisfaction according to specialty, expertise, country, and activity sector.

| Specialty | Country | Activity sector | Years of experience | P-value |
|-----------|---------|----------------|--------------------|---------|
| Surgeon Oncologist | Algeria Morocco Mauritania Tunisia | Public Private | <10 years >10 years | |
| **Priorities (Mean ± SD)** | | | | |
| Cure | 3.66 ± 1.36 | 4.22 ± 0.96 | 0.035 | | |
| Symptoms relief | 4.55 ± 0.79 | 4.85 ± 0.36 | 0.019 | | |
| Few side effects | 3.80 ± 1.06 | 4.27 ± 0.84 | 0.023 | | |
| Few contraindications | 3.55 ± 1.02 | 4.08 ± 0.83 | 0.007 | | |
| Inexpensive | 3.39 ± 1.14 | 3.64 ± 1.11 | 0.287 | | |
| Good quality of life | 4.52 ± 0.90 | 4.86 ± 0.34 | 0.031 | | |
| **Satisfaction (Mean ± SD)** | | | | |
| PC of ovarian origin | 5.61 ± 2.83 | 5 ± 2.66 | 0.301 | | |
| PC of colorectal origin | 5.05 ± 2.77 | 4.58 ± 2.50 | 0.371 | | |
| PC of gastric origin | 3.30 ± 2.37 | 3.46 ± 2.71 | 0.984 | | |
| PC of PMP origin | 5.68 ± 3.35 | 4.90 ± 2.82 | 0.213 | | |
| The need of new treatment modalities | 8.02 ± 2.26 | 9.07 ± 0.98 | 0.05 | | |

The bold values mean significant value.
Souadka et al. Peritoneal Cancer Management in North Africa

FIGURE 2 | Main priorities in the treatment of peritoneal carcinomatosis.

a moderate degree of satisfaction and high perceived degree of effectiveness for HIPEC.

Previous studies on the acceptance of PC therapies portrayed a substantial variation in opinions according to factors such as specialty, experience, implementation of multidisciplinary tumor boards and availability of expert centers (13, 26, 33, 34), which could contribute to the underutilization of these treatments. Accordingly, we compared potential differences between specialists and according to years of expertise, activity sector as well as country. When comparing surgeons and oncologists' point of views, some differences in priorities and need for new therapies have been observed. However, no disagreement has been noted regarding chemotherapy and HIPEC use, except for PC of ovarian origin, for which HIPEC indications are still a subject of controversy (25, 35). The ongoing debate between oncologists, surgeons, and other non-oncologic specialists regarding PC has been established in previous studies (12, 13), with suggestions that a multidisciplinary discussion among different specialties is of utmost importance to overcome personal preferences and knowledge gaps, while deciding for treatment or even referral suitability (36, 37). In our study, 89.3% of specialists reported discussing their cases in multidisciplinary team meetings.

In resource restricted contexts such as in the North African region, the prioritization and indications for the curative treatment may also face the constraints of limited critical care and surgical resources management and expertise (22, 38-41). In fact, while only 26.2% of our respondents reported having access to HIPEC, a similar study on practice patterns in PC from the USA identified 65.8% of its participants as having easy access to a HIPEC and CRS specialists, with 42.7% being in the same hospital (33). In such settings, the world health organization (WHO) has identified the private sector as an additional asset allowing the provision of infrastructure, support services, medicines and medical products, as well as a solution to some financial challenges (42). As such, we choose to include the private sector in our analysis, which indeed demonstrated that the significantly higher availability in the private sector of some therapies such as pressurized intraperitoneal chemotherapy and low dose radiotherapy didn’t necessarily yield a higher level of satisfaction in the available treatment modalities. Regardless of the activity sector, the level of expertise is considered a better reflection (22), especially as the PSM treatment learning curve can be steep and complex (43).

PSM management has undergone a tremendous change and is still subject to evolving with ongoing randomized clinical trials and emerging new techniques. However, this progress is
### TABLE 3 | Perceived clinical usefulness of systemic chemotherapy and HIPEC in resectable peritoneal metastasis.

|                      | Global population | Surgeons | Oncologists | Public | Private | P-value |
|----------------------|-------------------|----------|-------------|--------|---------|---------|
|                      | Poor              | Moderate | High        | Poor   | Moderate| High    |
| Systemic chemotherapy|                   |          |             |        |         |         |
| Colorectal origin    |                   |          |             |        |         |         |
| First-line intention | 14 (13.6)         | 45 (43.7)| 44 (42.7)   | 9 (20.5)| 21 (47.7)| 14 (31.8) |
|                      | 0.079             |          |             |        |         |         |
|                     |                    |          |             |        |         |         |
| Second-line intention| 12 (11.7)         | 37 (35.9)| 54 (52.4)   | 6 (13.6)| 13 (29.5)| 25 (56.6) |
|                      | 0.030             |          |             |        |         |         |
|                      |                    |          |             |        |         |         |
| Gastric origin       |                   |          |             |        |         |         |
| First-line intention | 32 (31.1)         | 30 (29.1)| 41 (39.8)   | 15 (34.1)| 11 (25.9)| 18 (40.9) |
|                      | 0.029             |          |             |        |         |         |
|                     |                    |          |             |        |         |         |
| Second-line intention| 41 (40.8)         | 31 (30.1)| 30 (29.1)   | 17 (38.6)| 12 (27.3)| 15 (34.1) |
|                      | 0.768             |          |             |        |         |         |
|                      |                    |          |             |        |         |         |
| Ovarian origin       |                   |          |             |        |         |         |
| Second-line intention| 6 (5.8)           | 10 (9.7)| 87 (84.5)   | 5 (11.4)| 6 (13.6)| 33 (75)   |
|                      | 0.044             |          |             |        |         |         |
|                     |                    |          |             |        |         |         |
| Third-line intention | 40 (39.2)         | 32 (31.3)| 30 (29.4)   | 16 (36.6)| 12 (27.3)| 16 (36.6) |
|                      | 0.72              |          |             |        |         |         |
|                      |                    |          |             |        |         |         |
| HIPEC                |                   |          |             |        |         |         |
| Ovarian origin       | 11 (10.7)         | 41 (39.8)| 51 (49.5)   | 5 (11.4)| 13 (29.5)| 26 (59.1) |
|                      | 0.858             |          |             |        |         |         |
|                     |                    |          |             |        |         |         |
| Colorectal origin    | 22 (21.4)         | 38 (36.9)| 43 (41.7)   | 9 (20.5)| 17 (38.6)| 18 (40.9) |
|                      | 0.894             |          |             |        |         |         |
|                     |                    |          |             |        |         |         |
| Gastric origin       | 47 (45.6)         | 40 (38.8)| 16 (15.5)   | 18 (40.9)| 17 (38.6)| 9 (20.5)   |
|                      | 0.790             |          |             |        |         |         |
|                     |                    |          |             |        |         |         |
| PMP origin           | 7 (6.8)           | 20 (19.4)| 76 (73.8)   | 4 (9.1)| 9 (20.5)| 31 (70.5) |
|                      | 0.416             |          |             |        |         |         |

The bold values mean significant value.
also perceived as chaotic with many methodological variations according to patients, type and stage of carcinomatosis (44). This is why there is a need for strong collaborations between different specialists and even countries which were more successful in some areas, in order to ensure knowledge dissemination. The creation of organizations could also be a step forward toward consolidating efforts for the effective implementation of these innovative therapies as per the IDEAL framework, as well as developing guidelines regarding patient selection and therapy standardization (44–46). In our context, only 9.7% of respondents reported complying with the peritoneal surface oncology group international guidelines, which could reflect the need for a regional dialogue and a possible adaptation of these recommendations to the North African context, especially as no dissimilarities have been noted between four countries.

This study is exploratory research with some limitations. Firstly, participants’ selection was done through designated referees from each country who were in charge of contacting centers, which could result in some selection and reach bias. That being said, all declared cancer care centers in the region were contacted. Also, gynecological surgeons were under-represented in this group, which is due to the fact that gynecological oncological surgery is mostly performed by general oncological surgeons in the North African setting.

Notwithstanding these limitations, this is the first study addressing the current opinions in the North African region, while capturing the differences between specialties and activity sectors, as well as reflecting the real picture of practice in a region where little published data is available on the management of PC.

CONCLUSION

The assessment of current opinions and knowledge on peritoneal surface malignancy in the North African region indicates a low satisfaction with currently available treatment options and different perspectives between medical oncologists and surgeons. In spite of that, there was a notable homogeneity in treatment practices, which could reflect the possibility of developing a North African collaboration with regional guidelines that allow the adaptation of international recommendations to peritoneal surface malignancy management and that could serve as a template for other low and middle income settings.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

AS, SB, and MH have contributed to the conception and the design of the study. AS, SB, HE, AM, MAb, and JB have contributed to the acquisition of the data. AS, SB, and HE contributed to the analysis and the interpretation of data. AS and HE wrote the first draft. MM, AB, and MH critically reviewed the draft for important intellectual content. MAy, FK, ZK, YB, BE, and RM were involved in revising critically the corrected manuscript. All authors read and gave the final approval of the version to be published.

FUNDING

Publication fees supported by the Association Cancer Espoir, Rabat, Morocco.

ACKNOWLEDGMENTS

The authors would like to thank the board of the AMFROM, the Moroccan Society of Digestive Surgery (SMCD), the Tunisian Society of Surgery (ATS), and Algerian Society of Surgery (ASS), all the participant to the survey and Miss Hanane Benkouya for their support.

SUPPLEMENTARY MATERIAL

The Supplemental Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.798523/full#supplementary-material

REFERENCES

1. Eng OS, Turaga KK. Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer. J Surg Oncol. (2019) 119:613–5. doi: 10.1002/jso.25438
2. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. (2004) 22:3284–92. doi: 10.1200/jco.2004.10.012
3. Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. (2015) 22:2958–64. doi: 10.1245/s10434-015-3837-5
4. Manzanedo I, Pereira F, Rihuete Caro C, Pérez-Viejo E, Serrano Á, Gutiérrez Calvo A, et al. Cytoreductive Surgery and Hyperthermic Intrapertoneal Chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish group of peritoneal oncologic surgery (GECOP). Ann Surg Oncol. (2019) 26:2615–21. doi: 10.1245/s10434-019-07450-4
5. Honoré C, Goéré D, Messager M, Souadka A, Dumont F, Piessen G, et al. Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: results of a multicentre retrospective study. Eur J Surg Oncol. (2013) 39:235–41. doi: 10.1016/j.ejso.2012.12.013
6. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C, et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg. (2011) 254:884–93; discussion 893. doi: 10.1097/SLA.0b013e3182352647
7. van Driel WJ, Kooie SN, Sikoerska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. (2018) 378:230–40. doi: 10.1056/NEJMoa1708618
8. Chu TA, Moran BJ, Sugarbaker PH, Levine EA, Gleen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. (2012) 30:2449–56. doi: 10.1200/JCO.2011.39.7166

9. Struller F, Horvath P, Solass W, Weinreich F-J, Strumberg D, Kokkalis MK, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. (2019) 11:1758835919846402. doi: 10.1177/1758835919846402

10. Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. (2016) 14:128. doi: 10.1186/s12957-016-0892-7

11. Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, et al. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. (2019) 11:1758835919846402. doi: 10.1177/1758835919846402

12. Wang W, Tan GHC, Skanthakumar T, Chia CS, Soo KC, Teo MCC. Positive Practice Environments in Morocco: an exploratory study. World J Gastrointest Oncol. (2016) 8:279–100. doi: 10.1097/CCO.0000000000000659

13. Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, Deraco M. Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C-based HIPEC: a comparative study using the Peritoneal Surface Disease Severity Score (PSDSS). Ann Surg Oncol. (2020) 27:98–06. doi: 10.1245/s10434-019-07935-2

14. Brandl A, Westbrook S, Nunn S, Arbuthnot-Smith E, Mulsow J, Yousuff H, et al. Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting. BJS Open. (2020) 4:260–7. doi: 10.1002/bjs5.50256

15. Serpel U, Melis M, Newman E, Pachter HL, Berman RS. The development of a peritoneal surface malignancy program: a tale of three hospitals. J Cancer Educ. (2012) 27:670–5. doi: 10.1007/s13187-012-0352-2

16. González Bayón L, Sugarbaker PH, Gonzalez Moreno S, Vazquez V de l, Alves S, Moran BI. Initiation of a program in peritoneal surface malignancy. Surg Oncol Clin N Am. (2003) 12:741–53. doi: 10.1016/S1055-3207(03)00032-2

17. Barrios P, Ramos Bernadó M, Crusellas O, Sabía D, Bijedic L. SO-31 Centralization of care leads to optimal selection and outcomes for patients with peritoneal metastases of colorectal cancer: The Catalan region program. Ann Surg Oncol. (2020) 27:5203–6. doi: 10.1245/s10434-020-08446-2

18. Ruff P, Al-Sukhun S, Blanchard C, Shulman LN. Access to cancer therapeutics in low- and middle-income countries: a systematic review. Int J Clin Oncol. (2020) 25:1061–6. doi: 10.1007/s12957-020-00538-1

19. Martín D, Grasa F, Soys, Ashwin KR, Maheshwari A, Hübner M, et al. Current opinion on peritoneal carcinomatosis: a survey of the Indian Society of Peritoneal Surface Malignancies (ISPSM). J Gastrointest Cancer. (2020) 52:1061–6. doi: 10.1007/s12920-020-00538-1

20. Vermorken JB, van Dam P, Brand A. HIPEC in advanced epithelial ovarian cancer: why is there controversy? Curr Opin Oncol. (2020) 32:451–8. doi: 10.1097/CCO.0000000000000659

21. Yoo HJ, Hong JI, Ko YB, Lee M, Kim Y, Han HY, et al. Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncolgic surgeons. World J Surg Oncol. (2018) 16:92. doi: 10.1186/s12957-018-1377-7

22. Krennngbur G, van der Speeten K, de Hingh I. Peritoneal metastases from colorectal cancer: defining and addressing the challenges. Front Oncol. (2021) 11:650098. doi: 10.3389/fonc.2021.6 0098

23. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res. (1996) 82:79–100. doi: 10.1007/978-1-4613-2475-5.6

24. Rihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. (2016) 7:52307–16. doi: 10.18632/oncotarget.10760

25. Yonemura Y, Elnemr A, Endou Y, Hirano M. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. (2010) 2:85–97. doi: 10.4251/wjgo.v2.1.85

26. Chia CS, Tan GHC, Lim C, Soo KC, Teo MCC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. (2016) 23:2905–13. doi: 10.1245/s10434-016- 5023-0

27. Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. Curr Oncol. (2020) 27:146–54. doi: 10.3747/co.27.6033

28. Bernaiche T, Emery E, Bijelic L. Practice patterns, attitudes, and knowledge among physicians regarding cytoreductive surgery and HIPEC for patients with peritoneal metastases. Planta Peritoneum. (2018) 3:0170025. doi: 10.1515/pp-2017-0025

29. Spiegel G, Schmocker S, Huang H, Victor JC, Law C, McCart JA, et al. Physicians’ awareness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer carcinomatosis. Can J Surg. (2013) 56:237–42. doi: 10.1503/cjso.003912

30. Friedich M, Friedrich D, Kraft C, Kuhn W, Rogmans C. HIPEC for ovarian cancer: A controversial discussion. In: Gwo-Yax H, Webber K, editors. Ovarian Cancer - Updates in Tumour Biology and Therapeutics. IntechOpen (2021). p. 150–2.

31. Ramírez-Pérez CP, Moreno-Ruiz FJ, Pérez-Daga JA. A multidisciplinary approach for peritoneal carcinomatosis and bilobar liver metastases from colorectal cancer: case report and review of the literature. World J Surg Oncol. (2015) 13:233. doi: 10.1186/s12957-015-0654-y

32. Siddiqui J, Brown K, Zahid A, Young CJ. Current practices and barriers to referral for cytoreductive surgery and HIPEC among colorectal surgeons: a binational survey. Eur J Surg Oncol. (2020) 46:166–72. doi: 10.1016/j.ejso.2019.09.007

33. Shariff F, Bischof D, Govindarajan A, Prince R, Burkes R, Haase E, et al. Evidence-based strategies for the treatment of peritoneal malignancies during health care resource restriction: the COVID-19 pandemic. Curr Oncol. (2020) 27:8:40–51. doi: 10.3390/cu2704040

34. Grasa F, Soys, Ashwin KR, Maheshwari A, Hübner M, et al. Current opinion on peritoneal carcinomatosis: a survey of the Indian Society of Peritoneal Surface Malignancies (ISPSM). J Gastrointest Cancer. (2020) 52:1061–6. doi: 10.1007/s12920-020-00538-1

35. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res. (1996) 82:79–100. doi: 10.1007/978-1-4613-2475-5.6

36. Souadka A, Benkabbou A, Al Ahmadi B, Boutayeb S, Majbar MA. Preparing African anticancer centres in the COVID-19 outbreak. Lancet Oncol. (2020) 21:e237. doi: 10.1016/S1470-2045(20)30216-3
41. Bensbih S, Souadka A, Diez AG, Bouksour O. Patient centered care: focus on low and middle income countries and proposition of new conceptual model. *J Med Surg Res.* (2020) 1:755–63. doi: 10.46327/msrjg.1.000000000000168

42. Clarke D, Doerr S, Hunter M, Schmets G, Soucat A, Paviza A. The private sector and universal health coverage. *Bull World Health Organ.* (2019) 97:434–5. doi: 10.2471/BLT.18.225540

43. Souadka A, Benkabbou A, Majbar MA, Essangri H, Amrani L, Ghannam A, et al. CRS and HIPEC: the need for an adaptable learning curve model. *J Surg Oncol.* (2020) 122:1187–8. doi: 10.1002/jso.26123

44. Pocard M. Peritoneal carcinomatosis is multifaceted, treatment requires expertise and collaboration with other health care personnel: new avenues of research are open. *J Visc Surg.* (2019) 156:471–2. doi: 10.1016/j.jviscsurg.2019.09.006

45. Esquivel J, Stojadinovic A, Levine EA. The American Society of Peritoneal Surface Malignancies (ASPSM). *Ann Surg Oncol.* (2011) 18:218–9. doi: 10.1245/s10434-010-1402-8

46. Tate SJ, Torkington J. Pressurized intraperitoneal aerosol chemotherapy: a review of the introduction of a new surgical technology using the IDEAL framework. *BJS Open.* (2020) 4:206–15. doi: 10.1002/bjs5.50257

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Souadka, Essangri, Makni, Abid, Ayadi, Ksantini, Kordjani, Ballah, Bouka, Benkabbou, Majbar, El Khannoussi, Mohsine, Boutayeb and Hubner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.